Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 May;2(3):293-7.
doi: 10.2217/imt.10.22.

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation

Alexander J Muller, Laura Mandik-Nayak, George C Prendergast
Editorial

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation

Alexander J Muller et al. Immunotherapy. 2010 May.

Erratum in

  • Immunotherapy. 2010 Jul;2(4):590
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial & Competing interests disclosure

This work is supported by the Lankenau Hospital Foundation (to Alexander J Muller, Laura Mandik-Nayak and George C Prendergast). Alexander J Muller is the recipient of a Lance Armstrong Foundation Grant. George C Prendergast is the recipient of NIH Grants CA109542, CA82222 and CA100123. Alexander J Muller, Laura Mandik-Nayak and George C Prendergast declare intellectual property interests related to indoleamine 2,3-dioxygenase (IDO). Alexander J Muller and George C Prendergast also declare financial interests, grant support and consultancy roles with New Link Genetics Corporation, which is engaged in the clinical development of IDO inhibitors for the purpose of treating cancer and other diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Muller AJ, Scherle PA. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006;6(8):613–625. - PubMed
    1. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396(1):203–213. - PubMed
    1. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082–7087. - PubMed
    1. Shimizu T, Nomiyama S, Hirata F, Hayaishi O. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem. 1978;253(13):4700–4706. - PubMed
    1. Yoshida R, Hayaishi O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 1978;75(8):3998–4000. - PMC - PubMed

Publication types

MeSH terms

Substances